Drug intelligence / Profile preview

capmatinib + osimertinib

Development stage: Unknown
Lead developer: Syngenta
Modality: Small Molecules
Administration: Oral

Overview

capmatinib + osimertinib is a combination therapy for advanced non-small cell lung cancer (NSCLC) with specific genetic alterations. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor, and capmatinib is a selective MET tyrosine kinase inhibitor. The combination targets both EGFR and MET signaling pathways, which are commonly implicated in NSCLC progression and resistance to single-agent targeted therapies. This approach aims to overcome resistance mechanisms such as MET amplification or activating mutations that emerge during treatment with EGFR inhibitors.

Targets

MET (Mesenchymal-epithelial transition factor receptor)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on capmatinib + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capmatinib + osimertinib.

Explore the full profile